Raje Noopur, Anderson Kenneth C
Jerome Lipper Multiple Myeloma Center, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA.
Curr Opin Oncol. 2002 Nov;14(6):635-40. doi: 10.1097/00001622-200211000-00008.
The demonstration of increased angiogenesis in cancer pathogenesis prompted the use of thalidomide in both solid tumors and hematologic malignancies. Its broad spectrum of actions besides its antiangiogenic potential, specifically, its immunomodulatory properties, antiinflammatory actions, and direct effect on tumor cells and their microenvironment, provides an alternative strategy in the armamentarium against cancer. Thalidomide is being evaluated for treatment of hematologic cancers like multiple myeloma and myelodysplasia, and solid tumors like lung, breast, renal, and colon cancer. Thalidomide analogues, the immunomodulatory drugs have increased potency and have demonstrated efficacy and reduced toxicity in phase I and II clinical studies. This article reviews both laboratory-based and clinical studies with thalidomide and the immunomodulatory drugs and their application in different cancers.
癌症发病机制中血管生成增加的证据促使沙利度胺被用于实体瘤和血液系统恶性肿瘤。除了其抗血管生成潜力外，它还具有广泛的作用，特别是其免疫调节特性、抗炎作用以及对肿瘤细胞及其微环境的直接影响，这为抗癌药物库提供了一种替代策略。沙利度胺正在被评估用于治疗血液系统癌症，如多发性骨髓瘤和骨髓增生异常综合征，以及实体瘤，如肺癌、乳腺癌、肾癌和结肠癌。沙利度胺类似物，即免疫调节药物，效力有所增强，并且在I期和II期临床研究中已证明具有疗效且毒性降低。本文综述了基于实验室的研究以及沙利度胺和免疫调节药物的临床研究及其在不同癌症中的应用。
